Grifols | GRFS - Operating Expenses


Grifols reported EUR1.77B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.19M 428K Sep/2025
Arca Biopharma USD 25.09M 5.23M Mar/2025
aTyr Pharma USD 26.94M 6.63M Sep/2025
Bio Path USD 3.24M 616K Mar/2025
Brainstorm Cell Therapeutics USD 3.09M 100K Mar/2025
Capricor Therapeutics USD 24.98M 6.15M Mar/2025
Cara Therapeutics USD 4.96M 2.38M Mar/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Grifols EUR 1.77B 22.04M Sep/2025
Immunic USD 25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
TherapeuticsMD USD 1.41M 50K Jun/2024